| Number |
Study Title |
Groups |
Recruitment |
| HNCIG‑1 |
Post-operative Adjuvant Treatment for HPV-positive Tumours (PATHOS) |
NCRI, EORTC |
Open |
| HNCIG‑2 |
EORTC 1420: Study Assessing The “Best of” Radiotherapy vs the “Best of” Surgery in Patients With Oropharyngeal Carcinoma (Best Of) |
EORTC, SAKK |
Open |
| HNCIG‑3 |
CompARE: Phase III randomised controlled trial Comparing Alternative Regimens for escalating treatment of intermediate and high-risk oropharyngeal cancer |
NCRI, TMC |
Open |
| HNCIG‑4 |
Determination of Cetuximab Versus Cisplatin Early and Late Toxicity Events in HPV+ OPSCC (De-ESCALaTE) |
NCRI, Cancer Trials Ireland |
Open |
| HNCIG‑5 |
NRG HN001: Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA |
NRG Oncology, NCTN, HKNPCSG, Singapore NCC, Fudan University |
Open |
| HNCIG‑6 |
NRG HN002: Reduced-Dose Intensity-Modulated Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Oropharyngeal Cancer |
NRG Oncology, NCTN, CCTG |
Closed to accrual |
| HNCIG‑7 |
EORTC-1219-ROG-HNCG: A blind randomized multicenter study of accelerated fractionated chemo-radiotherapy with or without the hypoxic radiosensitizer nimorazole (Nimoral), using a 15 gene signature for hypoxia in the treatment of squamous cell carcinoma of the head and neck |
EORTC, DAHANCA, TROG |
Closed to accrual |